{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:49Z","timestamp":1786119409102,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/cad.0b013e3282fcbbf7","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T01:51:44Z","timestamp":1267062704000},"page":"541-545","source":"Crossref","is-referenced-by-count":17,"title":["Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer"],"prefix":"10.1097","volume":"19","author":[{"given":"Hans-Georg","family":"Strauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Karbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lautenschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Persing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Thomssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-11-20210203","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"R3-11-20210203","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bjc.1996.193","article-title":"Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group","volume":"73","author":"Goebel","year":"1996","journal-title":"Br J Cancer"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage-designs for phase II clinical trials","volume":"10","author":"Simon","year":"1998","journal-title":"Control Clin Trials"},{"key":"R14-11-20210203","first-page":"1567","article-title":"Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized double-blind clinical trial using a canine model","volume":"4","author":"Vail","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R20-11-20210203","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol"},{"key":"R21-11-20210203","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e3282fcbbf7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:30Z","timestamp":1786039890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200806000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3282fcbbf7","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}